The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.
Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease
Open accessAbstract
Nonalcoholic fatty liver disease is strongly associated with hepatic insulin resistance and type 2 diabetes mellitus, but the molecular signals linking hepatic fat accumulation to hepatic insulin resistance are unknown. Three days of high-fat feeding in rats results specifically in hepatic steatosis and hepatic insulin resistance. In this setting, PKCepsilon, but not other isoforms of PKC, is activated. To determine whether PKCepsilon plays a causal role in the pathogenesis of hepatic insulin resistance, we treated rats with an antisense oligonucleotide against PKCepsilon and subjected them to 3 days of high-fat feeding. Knocking down PKCepsilon expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling. Furthermore, we show that PKCepsilon associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro. These data support the hypothesis that PKCepsilon plays a critical role in mediating fat-induced hepatic insulin resistance and represents a novel therapeutic target for type 2 diabetes.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In rats, 3 days of high-fat feeding causes hepatic steatosis and hepatic insulin resistance with specific activation of PKCε. Knocking down PKCε with an antisense oligonucleotide prevents fat-induced hepatic insulin resistance and improves hepatic insulin signaling, apparently by preventing PKCε from directly inhibiting insulin receptor kinase activity.
Key findings
- PKCε ASO specifically reduced PKCε expression in liver and white adipose tissue, but not muscle, without changing PKCδ; it caused no hepatotoxicity (AST: saline 57 ± 0.3 vs. PKCε 68 ± 3; ALT: saline 76 ± 3 vs. PKCε 87 ± 5), similar weight gain, and no differences in IL-6, leptin, adiponectin, or resistin.
- Despite unchanged liver triglyceride and DAG content and identical fasting plasma glucose, PKCε ASO lowered fasting plasma insulin by approximately 50% versus saline- and control ASO-treated rats, and improved hepatic insulin action: greater suppression of hepatic glucose production during hyperinsulinemic-euglycemic clamping, modestly increased whole-body glucose disposal, nearly 2-fold higher epididymal white adipose tissue glucose uptake, and greater suppression of plasma fatty acids.
- In PKCε ASO-treated rats, insulin increased IRS2 tyrosine phosphorylation approximately 300% above basal, whereas saline and control ASO rats failed to increase IRS2 phosphorylation; insulin-stimulated AKT2 activity increased approximately 400% versus approximately 50% in controls. Adipose insulin-stimulated AKT2 activity was 221% ± 16% in PKCε ASO rats versus 32% ± 11% and 23% ± 20% in saline- and control ASO-treated rats.
- PKCε coimmunoprecipitated with the insulin receptor in vivo, and increasing molar ratios of PKCε to insulin receptor-β dose-dependently decreased insulin receptor-β tyrosine kinase activity in vitro. Liver insulin receptor kinase activation by insulin was diminished in saline- and control ASO-treated high-fat-fed rats but preserved in PKCε ASO-treated rats.
Methods
- Male Sprague-Dawley rats weighing approximately 250 g were treated for 4 weeks with saline, control ASO, or PKCε ASO at 75 mg/kg per week by intraperitoneal injection, then fed a high-fat diet (26% carbohydrate, 59% fat, 15% protein calories; safflower oil major constituent) for 3 days.
- Hyperinsulinemic-euglycemic clamp studies used [6,6-2H]glucose and 2-deoxy-d-[1-14C]glucose to assess basal and insulin-stimulated glucose turnover and tissue glucose uptake; liver triglyceride and DAG, plasma hormones and fatty acids, insulin signaling, PKC expression, and insulin receptor kinase activity were measured.
- PKCε ASO was ISIS-232697; control ASO was ISIS-141923. A separate group of similarly treated rats underwent 20 minutes of hyperinsulinemic-euglycemic clamping for insulin signaling assays. Statistics used 1-way ANOVA followed by Tukey’s HSD test, with P < 0.05 considered significant.
Limitations
- The paper does not include a dedicated limitations section. It states that the role of PKCε in the adipocyte is uncertain and that a similar mechanism in patients with diabetes is hypothesized based on prior human data, not directly tested here.
- Evident from the text: the findings are in male Sprague-Dawley rats after only 3 days of high-fat feeding and 4 weeks of ASO treatment, so they cannot establish long-term causality, safety, or efficacy in human NAFLD or type 2 diabetes.
- Evident from the text: PKCε ASO reduced PKCε in liver and white adipose tissue but not muscle, and muscle glucose uptake was unchanged, limiting conclusions about skeletal muscle insulin action.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 21 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show that PKCε associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro.”
- Also stated in: § PKCε interferes with insulin receptor activation. · plain
“Immunoprecipitation of insulin receptor from liver protein extracts pulled down PKCε, and immunoprecipitation of PKCε also pulled down insulin receptor (Figure 4D).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · boosted
“First, we show here that PKCε and insulin receptor directly associate in vivo, as they each coimmunoprecipitate the other.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε interferes with insulin receptor activation. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The reduction in mRNA translated into a similar reduction in PKCε protein content relative to that in saline-treated animals (Figure 1B).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Knocking down PKCε expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling.”
- Also stated in: § PKCε ASO treatment does not alter liver lipids but lowers plasma insulin. · plain
“Under hyperinsulinemic conditions, suppression of hepatic glucose production was markedly greater in the PKCε group compared with the saline and control ASO groups (Figure 3B).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · boosted
“Here we establish that decreasing PKCε expression protects against the development of hepatic insulin resistance and improves adipose insulin action by augmenting the activity of the insulin signaling pathway.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε ASO treatment does not alter liver lipids but lowers plasma insulin. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, PKCε ASO treatment did not alter muscle PKCε expression.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Knocking down PKCε expression protects rats from fat-induced hepatic insulin resistance and reverses fat-induced defects in hepatic insulin signaling.”
- Also stated in: § PKCε ASO treatment improves insulin signaling. · plain
“In contrast, in rats treated with PKCε ASO, insulin increased IRS2 tyrosine phosphorylation approximately 300% above basal (Figure 4B).”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
“Thus, PKCε ASO treatment prevents the defects in insulin signaling that lead to the development of hepatic insulin resistance.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § PKCε ASO treatment improves insulin signaling. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The amount of PKCδ was unchanged by PKCε ASO treatment.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin receptor tyrosine phosphorylation was similarly increased above basal by approximately 50% in all 3 groups.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment improves insulin signaling.
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition to the changes in hepatic insulin action, there was a modest but significant increase in insulin-stimulated whole-body glucose disposal in the PKCε ASO-treated animals (Figure 3C).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment does not alter liver lipids but lowers plasma insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, analysis of the insulin signaling pathway demonstrated that insulin signaling was improved in PKCε-treated rats.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The lower insulin concentration approaches values seen in rats on regular (low-fat) chow and suggests improved hepatic insulin sensitivity.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO treatment does not alter liver lipids but lowers plasma insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 10
- Probably not a substantial claim. 4
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PKCε ASO treatment specifically reduced PKCε expression in liver and white adipose tissue after 4 weeks of treatment at 75 mg/kg per week (Figure 1A).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, we show that PKCε associates with the insulin receptor in vivo and impairs insulin receptor kinase activity both in vivo and in vitro.”
- Also stated in: § PKCε interferes with insulin receptor activation. · hedged
“Increasing molar ratios of PKCε to insulin receptor-β resulted in a dose-dependent decrease in insulin receptor-β tyrosine kinase activity, suggesting that PKCε could directly inhibit insulin receptor kinase activity (Figure 4E).”
- Also stated in: § PKCε interferes with insulin receptor activation. · plain
“In contrast, insulin receptor obtained from PKCε ASO-treated rats had preserved activation of the insulin receptor kinase.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § PKCε interferes with insulin receptor activation. · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Neither fasting plasma glucose concentrations nor basal hepatic glucose production rates were affected by PKCε ASO therapy.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation of insulin receptor from liver protein extracts pulled down PKCε, and immunoprecipitation of PKCε also pulled down insulin receptor (Figure 4D).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε interferes with insulin receptor activation.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“PKCε ASO specifically inhibits PKCε, without altering the levels of other PKC isoforms.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically, rats remained free of hepatotoxicity, as reflected by the absence of transaminase elevation (aspartate aminotransferase [AST]: saline, 57 ± 0.3; PKCε, 68 ± 3; alanine aminotransferase [ALT]: saline, 76 ± 3; PKCε, 87 ± 5), and exhibited similar weight gain (Figure 1C) across all 3 groups.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > PKCε ASO is specific and effective.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Amelioration of nonalcoholic fatty liver disease (NAFLD) in patients with T2DM by weight reduction is associated with reversal of hepatic insulin resistance and a return to normoglycemia (9).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
- Not checked yetcites [9] Petersen, 2005, Diabetes. source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“An alternate hypothesis is that the development of hepatic steatosis per se causes hepatic insulin resistance.”
- Also stated in: § Introduction · boosted
“multiple lines of evidence support the role of intrahepatic fat in causing hepatic insulin resistance (7)(8)(9)(10)(11)(12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
Tests✗ Asserted: fails✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true.
- Also stated in: § Introduction · boosted
None of the sources cited for this claim have been checked yet.
In the paper
“Preventing fat accumulation by inhibiting lipid synthesis via disruption of the mitochondrial acyl-CoA:glycerol-sn-3-phosphate acyltransferase (7) or promoting fat oxidation using either the mitochondrial uncoupler 2,4-dinitrophenol (10) or inhibition of acetyl-CoA carboxylase-1 and -2 (12) prevents PKCε activation and hepatic insulin resistance.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In this setting, PKCε, but not other isoforms of PKC, is activated.”
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
“we observed that the development of diet-induced hepatic steatosis was associated with the activation of PKCε (7,10,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > Abstract
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § NAFLD is strongly linked to hepatic insulin resistance, and T2DM · plain
None of the sources cited for this claim have been checked yet.
In the paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“This is important since DAG is a known activator of classic and novel isoforms of PKC and DAG concentrations have closely paralleled insulin resistance in other models (7,12).”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, in this model system, we specifically inhibit PKCε without altering other PKC isoforms or the concentration of PKC activators.”
§ Inhibition of protein kinase Cε prevents hepatic insulin resistance in nonalcoholic fatty liver disease > NAFLD is strongly linked to hepatic insulin resistance, and T2DM
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
ASOs are avidly taken up by the liver, where they inhibit specific genes of interest.
“ASOs are avidly taken up by the liver, where they inhibit specific genes of interest.”
The paper relies on this without support.
The control ASO does not have perfect complementarity to any known gene in public databases.
“The control ASO, ISIS-141923, has the sequence 5′-CCTTCCCT-GAAGGTTCCTCC-3′ and does not have perfect complementarity to any known gene in public databases.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is now strong evidence that nonalcoholic fatty liver disease has an important role in causing hepatic insulin resistance.1–3,23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [24]
In the citing paper
“Recent studies have shown that increased hepatocellular concentrations of diacylglycerol in nonalcoholic fatty liver disease lead to activation of the protein kinase C epsilon isoform, resulting in reduced insulin signaling and hepatic insulin resistance.23–27”
From Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease (2010) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Glucose tracer enrichment is identified as both M+6 and M+2
MinorThe methods describe the measured glucose enrichment as M+6, but then identify it as M+2 when specifying the mass ratio used. Both statements refer to the enrichment measurement for the same tracer.
“The atom percentage enrichment of glucoseM+6 was then measured by gas chromatographic/mass spectrometric analysis using a Hewlett-Packard 5890 gas chromatograph interfaced to a Hewlett-Packard 5971A mass-selective detector operating in the electron ionization mode (29).”
“GlucoseM+2 enrichment was determined from the m/z ratio 202:200.”
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Wild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
Kadowaki, T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29126 · Cited by 2,824
Özcan, U., Yilmaz, E., Özcan, L., Furuhashi, M., Vaillancourt, E., Smith, R. O., Görgün, C. Z., & Hotamisligil, G. S. (2006) · Science · doi:10.1126/science.1128294 · Cited by 2,413
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Self-citationGlobal Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030
Wild, S. H., Roglić, G., Green, A., Sicree, R. A., & King, H. O. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2569-a · Cited by 1,477
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Self-citationPetersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 497
ter Horst, K. W., Gilijamse, P. W., de Weijer, B. A., Kiliçarslan, M., Ackermans, M. T., Nederveen, A. J., Nieuwdorp, M., Romijn, J. A., & Serlie, M. J. M. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00182 · Cited by 70
Mechanism by which arylamine N -acetyltransferase 1 ablation causes insulin resistance in mice
Camporez, J. P., Wang, Y., Faarkrog, K., Chukijrungroat, N., Petersen, K. F., & Shulman, G. I. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716990115 · Cited by 67
Self-citationA role for phosphatidylcholine and phosphatidylethanolamine in hepatic insulin signaling
van der Veen, J. N., Lingrell, S., McCloskey, N. S., LeBlond, N. D., Galleguillos, D., Zhao, Y., Curtis, J. M., Sipione, S., Fullerton, M. D., Vance, D. E., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802117r · Cited by 65
Connaughton, R. M., McMorrow, A. M., McGillicuddy, F. C., Lithander, F. E., & Roche, H. M. (2016) · Proceedings of The Nutrition Society · doi:10.1017/s0029665116000070 · Cited by 63
Macronutrient Determinants of Obesity, Insulin Resistance and Metabolic Health
Wali, J. A., Solon‐Biet, S. M., Freire, T., & Brandon, A. E. (2021) · Biology · doi:10.3390/biology10040336 · Cited by 74
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Grattagliano, I., Montezinho, L. P., Oliveira, P. J., Frühbeck, G., Gómez‐Ambrosi, J., Montecucco, F., Carbone, F., Wieckowski, M. R., Wang, D. Q. ‐., & Portincasa, P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.020 · Cited by 66
Wendel, A. A., Li, L. O., Li, Y., Cline, G. W., Shulman, G. I., & Coleman, R. A. (2010) · Diabetes · doi:10.2337/db09-1380 · Cited by 63
Self-citationProtein Kinase C Epsilon Deletion in Adipose Tissue, but Not in Liver, Improves Glucose Tolerance
Brandon, A. E., Liao, B. M., Diakanastasis, B., Parker, B. L., Raddatz, K., McManus, S. A., O’Reilly, L., Kimber, E., van der Kraan, A. G. J., Hancock, D., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.013 · Cited by 65
“Similarly, knockdown of PKC 3in vivo using an antisense oligonucleotide was able to rescue the suppression of hepatic glucose production during hyperinsulinemic-euglycemic clamps in mice fed a HFD for 3 days (Samuel et al., 2007).”
BackgroundInfluentialGlycosphingolipids and Insulin Resistance
Aerts, J. M. F. G., Boot, R. G., van Eijk, M., Groener, J. E. M., Bijl, N., Lombardo, E., Biétrix, F., Dekker, N., Groen, A. K., Ottenhoff, R., et al. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0650-1_7 · Cited by 63
Visceral fat: A key mediator of NAFLD development and progression
Bansal, S., Vachher, M., Arora, T. K., Kumar, B., & Burman, A. (2023) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2023.200210 · Cited by 69
Divergent Role of Sphingosine 1-Phosphate on Insulin Resistance
Fayyaz, S., Japtok, L., & Kleuser, B. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000362990 · Cited by 62
(–)-Epicatechin in the control of glucose homeostasis: Involvement of redox-regulated mechanisms
Cremonini, E., Fraga, C. G., & Oteiza, P. I. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.11.010 · Cited by 65
Zheng, Z., Xu, Y.-Y., Liu, W., Zhang, Y., Zhang, C., Liu, H.-L., Zhang, X., Liu, R., Zhang, Y., Shi, M.-Y., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.11.012 · Cited by 61
Self-citationChanges in Cells Associated with Insulin Resistance
Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042397 · Cited by 78
“These changes reduce insulin-stimulated activation due to the phosphorylation of IRS-2, PI3K and Akt2 [185,186].”
BackgroundMatsuda, Y., Kobayashi, M., Yamauchi, R., Ojika, M., Hiramitsu, M., Inoue, T., KATAGIRI, T., Murai, A., & Horio, F. (2011) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.110452 · Cited by 63
Endoplasmic Reticulum Stress Promotes LIPIN2-Dependent Hepatic Insulin Resistance
Ryu, D., Seo, W., Yoon, Y.-S., Kim, Y.-N., Kim, S. S., Kim, H., Park, T., Choi, C. S., & Koo, S. (2011) · Diabetes · doi:10.2337/db10-1046 · Cited by 61
Huo, Y., Guo, X., Li, H., Xu, H., Halim, V., Zhang, W., Wang, H., Fan, Y.-Y., Ong, K. T., Woo, S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.370379 · Cited by 63
“and improvement of insulin-stimulated adipose tissue glucose uptake (10).”
BackgroundOteiza, P. I., Fraga, C. G., & Galleano, M. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101914 · Cited by 64
“Mechanistically, a pro-oxidant environment leads to the activation of redox-sensitive kinases, e.g. c-Jun N-terminal kinase 1/2 (JNK) [76,77], inhibitor of nuclear factor κB (IκB) kinase (IKK) [78]), and protein kinase C (PKC) [74,79].”
BackgroundShankar, E., Vykhovanets, E. V., Vykhovanets, O. V., MacLennan, G. T., Singh, R., Bhaskaran, N., Shukla, S., & Gupta, S. (2011) · The Prostate · doi:10.1002/pros.21425 · Cited by 60
Shimano, H. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2011.12.004 · Cited by 62
Papáčková, Z., Daňková, H., Páleníčková, E., Kazdová, L., & Cahová, M. (2012) · Physiological Research · doi:10.33549/physiolres.932394 · Cited by 60
“DAG is a known activator of several protein kinase C (PKC) isoforms of including PKCε which was delineated a specific role in the development of fat-induced insulin resistance in the liver (Samuel et al. 2004, Samuel et al. 2007).”
BackgroundLipid induced overexpression of NF-κB in skeletal muscle cells is linked to insulin resistance
Barma, P., Bhattacharya, S., Bhattacharya, A., Kundu, R., Dasgupta, S., Biswas, A., Bhattacharya, S., Roy, S. S., & Bhattacharya, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.014 · Cited by 59
“A recent report demonstrated that PKCε plays an important role in mediating lipid induced hepatic insulin resistance, as knocking down of PKCε expression reverses fat induced impairment of hepatic insulin signaling [46].”
BackgroundHepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 65
Ho, P., Lin, Y.-W., Tsui, Y.-C., Gupta, P. K., & Wei, L. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.09.012 · Cited by 59
“PKCε activation in liver and muscle is an important factor for impaired insulin-stimulated glucose disposal (Laybutt et al., 1999; Samuel et al., 2007).”
Frangioudakis, G., Burchfield, J. G., Narasimhan, S. R., Cooney, G. J., Leitges, M., Biden, T. J., & Schmitz‐Peiffer, C. (2009) · Diabetologia · doi:10.1007/s00125-009-1543-0 · Cited by 59
“The effect of PKCε ablation on glucose tolerance has been investigated by Prkce knockdown using specific oligonucleotides and by Prkce deletion; PKCε may play a role in hepatic insulin resistance in the short term [3], and also in insulin availability in the long term [4].”
BackgroundCheng, F., Han, L., Xiao, Y., Pan, C., Li, Y., Ge, X., Zhang, Y., Yan, S., & Wang, M. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b01253 · Cited by 59
A Balance of Lipid-Sensing Mechanisms in the Brain and Liver
Caspi, L., Wang, P. Y. T., & Lam, T. K. T. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.005 · Cited by 58
Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option?
Georgescu, E. F. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0110-2 · Cited by 59
Rahimi, Y., Camporez, J. P., Petersen, M. C., Pesta, D. H., Perry, R. J., Jurczak, M. J., Cline, G. W., & Shulman, G. I. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1419104111 · Cited by 60
Self-citationChapter 13 Phosphorylation of IRS Proteins
Sun, X., & Liu, F. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00613-4 · Cited by 57
Akie, T. E., Liu, L., Nam, M., Shi, L., & Cooper, M. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125617 · Cited by 56
“Upon activation, PKCε translocates from the cytosol to the membrane, where it phosphorylates insulin receptor beta, culminating in impaired insulin signaling [31,32].”
BackgroundRole of exercise-induced hepatokines in metabolic disorders
Ennequin, G., Sirvent, P., & Whitham, M. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00433.2018 · Cited by 54
Lipid signals and insulin resistance
Zhang, C., Klett, E. L., & Coleman, R. (2013) · Clinical Lipidology · doi:10.2217/clp.13.67 · Cited by 58
Greene, M. W., Burrington, C. M., Ruhoff, M. S., Johnson, A. K., Chongkrairatanakul, T., & Kangwanpornsiri, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.168575 · Cited by 54
Dongiovanni, P., Rametta, R., Fracanzani, A. L., Benedan, L., Borroni, V. N., Maggioni, P., Maggioni, M., Fargion, S. R., & Valenti, L. V. C. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-102 · Cited by 53
“Since increased hepatic fat, the pathological hallmark of NAFLD, negatively influences insulin signaling [27] and is associated with activation of fibrogenesis [28], we hypothesized that the Leu162Val variant of PPARa, previously associated with decreased hepatic lipolysis, dyslipidemia and type 2 diabetes (table 1),…”
BackgroundWang, C., Li, Y., Hao, M., & Li, W. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00345 · Cited by 53
“High levels of FFA and cholesterol metabolites can also activate the PKC and c-JNK-1 pathways, and lead to dysfunction of insulin receptor substrate 1 (IRS)-1 and IRS-2 tyrosine (Samuel et al., 2004, 2007; Kumashiro et al., 2011).”
BackgroundRegulation of age-associated insulin resistance by MT1-MMP-mediated cleavage of insulin receptor
Guo, X., Asthana, P., Gurung, S., Zhang, S., Wong, S. K. K., Fallah, S., Chow, C. F. W., Che, S., Zhai, L., Wang, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31563-2 · Cited by 49
Calcium Signaling As a Therapeutic Target for Liver Steatosis
Ali, E. S., & Petrovsky, N. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.02.005 · Cited by 50
Cantley, J., Burchfield, J. G., Pearson, G. L., Schmitz‐Peiffer, C., Leitges, M., & Biden, T. J. (2009) · Diabetes · doi:10.2337/db09-0132 · Cited by 53
“Functional inhibition of PKCε also improves glucose homeostasis in rodent models of type 2 diabetes (18,19) and reverses acute lipid-induced hepatic insulin resistance (20).”
BackgroundGhareeb, D. A., Hafez, H. S., Hussien, H. M., & Kabapy, N. F. (2011) · Metabolic Brain Disease · doi:10.1007/s11011-011-9261-y · Cited by 52
“Indeed, hepatic lipid accumulation results from an imbalance between lipid availability (from circulating lipid uptake or de novo lipogenesis) and lipid disposal (via fatty acid oxidation or triglyceride-rich lipoprotein secretion) and eventually triggering lipoperoxidative stress and hepatic injury (Samuel et al. 200…”
BackgroundSong, L., Li, Y., Qu, D. C., Ouyang, P.-L., Ding, X., Wu, P., Guan, Q., & Yang, L. (2019) · Food & Function · doi:10.1039/c9fo01570a · Cited by 53
Liver and insulin resistance: New wine in old bottle!!!
Patel, B. M., & Goyal, R. K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172657 · Cited by 51
Tumor Progression Locus 2 (TPL2) Regulates Obesity-Associated Inflammation and Insulin Resistance
Perfield, J. W., Lee, Y., Shulman, G. I., Samuel, V. T., Jurczak, M. J., Chang, E., Xie, C., Tsichlis, P. N., Obin, M. S., & Greenberg, A. S. (2011) · Diabetes · doi:10.2337/db10-0715 · Cited by 52
Self-citationPapáčková, Z., Páleníčková, E., Daňková, H., Ždychová, J., Škop, V., Kazdová, L., & Cahová, M. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-22 · Cited by 48
“Recently, it has been shown that fat-induced hepatic insulin resistance may result from activation of PKCε and its downstream targets [35,62].”
BackgroundBallestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., Targher, G., & Lonardo, A. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030355 · Cited by 48
Posadas‐Sánchez, R., López-Uribe, Á. R., Posadas‐Romero, C., Pérez‐Hernández, N., Rodrı́guez-Pérez, J. M., Ocampo-Arcos, W. A., Fragoso, J. M., Cardoso-Saldaña, G. C., & Vargas‐Alarcón, G. (2016) · Immunobiology · doi:10.1016/j.imbio.2016.08.008 · Cited by 48
“…in the subcutaeous tissue may contribute to the overflow of free fatty acids to the iver, which can accumulate as triglycerides and also can activate he protein kinase C resulting in inhibition of the hepatic insulin ignaling (Samuel et al., 2007) and development of subsequent nsulin resistance.”
BackgroundJani, S., Eira, D. D., Stefanovic, M., & Ceddia, R. B. (2022) · The Journal of Physiology · doi:10.1113/jp283552 · Cited by 53
Does Diacylglycerol Accumulation in Fatty Liver Disease Cause Hepatic Insulin Resistance?
Finck, B. N., & Hall, A. M. (2015) · BioMed Research International · doi:10.1155/2015/104132 · Cited by 47
“The link between PKCε activation and hepatic insulin resistance is supported in correlative fashion by several papers [12, 13, 16, 23, 24] and in more convincing fashion by “knocking down” PKCε in liver by RNAi [21].”
BackgroundInputs and outputs of insulin receptor
Du, Y., & Wei, T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0030-7 · Cited by 48
“In insulin-resistant liver, PKCε is the predominant activated PKC. PKCε inhibits insulin signaling by binding to IR and reducing its tyrosine kinase activity in hepatic steatosis (Samuel et al., 2007; Jornayvaz et al., 2011; Jornayvaz and Shulman, 2012).”
Alves, T. C., Befroy, D. E., Kibbey, R. G., Kahn, M., Codella, R., Carvalho, R. A., Petersen, K. F., & Shulman, G. I. (2011) · Hepatology · doi:10.1002/hep.24170 · Cited by 47
Self-citationCorreia, J. C., Massart, J., de Boer, J. F., Porsmyr‐Palmertz, M., Martínez-Redondo, V., Agudelo, L. Z., Sinha, I., Meierhofer, D., Ribeiro, V., Björnholm, M., et al. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.09.005 · Cited by 47
“After one week of high fat feeding, sufficient to induce hepatic steatosis in rodents [36],”
BackgroundIRS posttranslational modifications in regulating insulin signaling
Peng, J., & He, L. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0151 · Cited by 49
Interleukin‐32 Contributes to Human Nonalcoholic Fatty Liver Disease and Insulin Resistance
Dali‐Youcef, N., Vix, M., Costantino, F., Saghire, H. E., Lhermitte, B., Callari, C., D’Agostino, J., Perretta, S., Paveliu, S., Gualtierotti, M., et al. (2019) · Hepatology Communications · doi:10.1002/hep4.1396 · Cited by 49
The tail wagging the dog – regulation of lipid metabolism by protein kinase C
Schmitz‐Peiffer, C. (2013) · FEBS Journal · doi:10.1111/febs.12285 · Cited by 47
Inflammatory Signaling Involved in High-Fat Diet Induced Prostate Diseases.
Shankar, E., Bhaskaran, N., MacLennan, G. T., Liu, G., Daneshgari, F., & Gupta, S. (2015) · PubMed · Cited by 48
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21
Camporez, J. P., Asrih, M., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., & Jornayvaz, F. R. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0136 · Cited by 44
“In this case, hepatic insulin resistance was secondary to the accumulation of diacylgycerols (DAG), which are lipid intermediates known to activate protein kinase C epsilon (PKC3), which subsequently impairs insulin signaling (Samuel et al. 2007).”
BackgroundSelf-citationAbulizi, A., Perry, R. J., Camporez, J. P. G., Jurczak, M. J., Petersen, K. F., Aspichueta, P., & Shulman, G. I. (2017) · The FASEB Journal · doi:10.1096/fj.201700001r · Cited by 41
Self-citationAberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis
Li, B., Zhang, Z., Zhang, H., Quan, K., Lu, Y., Cai, D., & Ning, G. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0127 · Cited by 43
“…/o b Ch ow HF D Le an db /d b Le an ob /o Ch ow HF D Le a reports indicated that PKC3 is closely involved in FFAinduced hepatic insulin resistance and mitochondrial dysfunction in NAFLD (Morino et al. 2006, Samuel et al. 2007), and ETS1 could affect fat metabolism in obesity (Meerson et al. 2013).”
BackgroundTsujimoto, S., Kishina, M., Koda, M., Yamamoto, Y., Tanaka, K., Harada, Y., Yoshida, A., & Hisatome, I. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2674 · Cited by 43
Guo, W., Li, D., You, V., Li, W., Hu, B., Zhang, S., Miao, L., Xian, M., Zhu, Y. Z., & Shen, X. (2018) · The FASEB Journal · doi:10.1096/fj.201801894r · Cited by 44
Waraich, R. S., Weigert, C., Kalbacher, H., Hennige, A. M., Lutz, S. Z., Häring, H., Schleicher, E. D., Voelter, W., & Lehmann, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708588200 · Cited by 43
Sugimoto, M., Shimizu, Y., Zhao, S., Ukon, N., Nishijima, K., Wakabayashi, M., Yoshioka, T., Higashino, K., Numata, Y., Okuda, T., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2016.04.019 · Cited by 42
Bhat, N., Narayanan, A., Fathzadeh, M., Kahn, M., Zhang, D., Goedeke, L., Neogi, A., CARDONE, R. L., Kibbey, R. G., Fernandez-Hernando, C. F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153724 · Cited by 44
Self-citationAlshehade, S. A., Alshawsh, M. A., Murugaiyah, V., Asif, M., Alshehade, O., Almoustafa, H. A., & Zarzour, R. H. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120732 · Cited by 42
Regulation of Glucose Production in the Pathogenesis of Type 2 Diabetes
Sargsyan, A., & Herman, M. A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1195-5 · Cited by 42
Chen, W., Zhou, H., Saha, P., Li, L., & Chan, L. (2014) · Endocrinology · doi:10.1210/en.2014-1292 · Cited by 39
Dindia, L. A., Murray, J., Faught, E., Davis, T. L., Leonenko, Z., & Vijayan, M. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046859 · Cited by 41
“insulin resistance [39].”
Dietary approach in the treatment of nonalcoholic fatty liver disease
Ferolla, S. M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i24.2522 · Cited by 38
Peng, K., Pan, Y., Li, J., Khan, Z. A., Fan, M., Yin, H., Tong, C., Zhao, Y., Liang, G., & Zheng, C. (2016) · Scientific Reports · doi:10.1038/srep37160 · Cited by 38
Dallak, M. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.098 · Cited by 39
Implementation of environmental enrichment after middle age promotes healthy aging
McMurphy, T. B., Huang, W., Queen, N. J., Ali, S., Widstrom, K. J., Liu, X., Xiao, R., Siu, J. J., & Cao, L. (2018) · Aging · doi:10.18632/aging.101502 · Cited by 38
Lyu, K., Zhang, D., Song, J. D., Li, X., Perry, R. J., Samuel, V. T., & Shulman, G. I. (2021) · JCI Insight · doi:10.1172/jci.insight.139946 · Cited by 38
Self-citationHandy, R. M., & Holloway, G. P. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1151389 · Cited by 38
Kiràly, M. A., Campbell, J. E., Park, E., Bates, H. E., Yue, J. T. Y., Rao, V., Matthews, S. G., Bikopoulos, G. J., Rozakis-Adcock, M., Giacca, A., et al. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90575.2008 · Cited by 38
“resistance in response to a high-fat diet (73) and was previously found to be activated in ZF and ZDF models (73, 74).”
BackgroundMethodInfluentialThe effect of high‐fat diet and inhibition of ceramide production on insulin action in liver
Zabielski, P., Daniluk, J., Hady, H. R., Markowski, A. R., Imierska, M., Górski, J., & Błachnio-Zabielska, A. U. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27058 · Cited by 37
“Numerous studies reported that the accumulation of DAG negatively affects the insulin pathway in liver on IRS level (Galbo et al., 2013; Samuel et al., 2004, 2007; Samuel & Shulman, 2012; Shulman, 2000; Turinsky et al., 1990).”
BackgroundResultDPP4 deletion in adipose tissue improves hepatic insulin sensitivity in diet-induced obesity
Romacho, T., Sell, H., Indrakusuma, I., Röhrborn, D., Castañeda, T. R., Jeleník, T., Markgraf, D. F., Hartwig, S., Weiß, J., Al‐Hasani, H., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2019 · Cited by 37
THE ROLE OF INDY IN METABOLIC REGULATION
Willmes, D. M., & Birkenfeld, A. L. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201303020 · Cited by 38
Xu, W., Zhang, D., Ma, Y., Gaspar, R. C., Kahn, M., Nasiri, A. R., Murray, S., Samuel, V. T., & Shulman, G. I. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114746 · Cited by 38
Self-citationKamath, S., Chávez, A. O., Gastaldelli, A., Casiraghi, F., Halff, G. A., ABRAHAMIAN, G. A., Davalli, A. M., Bastarrachea, R. A., Comuzzie, A. G., Guardado‐Mendoza, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027617 · Cited by 36
“DAG and ceramides) that are proposed to induce hepatic insulin resistance, as demonstrated mainly, by studies in rodents [15,54,55,56].”
BackgroundUNIVERSIDADE DO EXTREMO SUL CATARINENSE - UNESC
Saúde, U. A. D., & Rosa, J. L. N. D. (2011) · Cited by 36
Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction
Mocciaro, G., & Gastaldelli, A. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_573 · Cited by 37
Guo, S., Gong, L., Shen, Q., & Xing, D. (2020) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2020.112075 · Cited by 37
Role of Diacylglycerol Kinases in Glucose and Energy Homeostasis
Massart, J., & Zierath, J. R. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.06.003 · Cited by 35
Dhurandhar, E. J., Krishnapuram, R., Hegde, V. K., Dubuisson, O. S., Tao, R., Dong, X. C., Ye, J., & Dhurandhar, N. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047813 · Cited by 35
“E4orf1 therefore may prevent buildup of fatty acid intermediates and attenuate subsequent inhibition of hepatic insulin signaling [24].”
BackgroundBrown, W. H., Gillum, M. P., Lee, H., Camporez, J. P., Zhang, X., Jeong, J. K., Alves, T. C., Erion, D. M., Guigni, B. A., Kahn, M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212887109 · Cited by 35
Self-citationThe macrophage at the intersection of immunity and metabolism in obesity
Samaan, M. C. (2011) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-3-29 · Cited by 34
“[61-69] and protein kinase C (PKC)[70-73] pathways are”
BackgroundDefining lipid mediators of insulin resistance: controversies and challenges
Metcalfe, L. K., Smith, G. C., & Turner, N. A. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0023 · Cited by 35
Mayer, A. E., Löffler, M. C., Loza‐Valdes, A., Schmitz, W., El‐Merahbi, R., Viera, J. T., Erk, M., Zhang, T., Braun, U., Heikenwälder, M. F., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aav9150 · Cited by 37
Pant, T., Uche, N., Juric, M., & Bosnjak, Z. J. (2023) · Antioxidants · doi:10.3390/antiox12040898 · Cited by 37
Yamamoto, T., Watanabe, K., Inoue, N., Nakagawa, Y., Ishigaki, N., Matsuzaka, T., Takeuchi, Y., Kobayashi, K., Yatoh, S., Takahashi, A., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m004234 · Cited by 36
Kim, J., Lee, Y., Kim, J. M., Lee, S. Y., Bae, M., Ahn, J. H., Han, D. C., & Kwon, B. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.10.018 · Cited by 34
Li, M.-R. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i38.14010 · Cited by 36
Biagioli, M., & Fiorucci, S. (2021) · Liver Research · doi:10.1016/j.livres.2021.08.003 · Cited by 33
“51 The liver biopsy from NAFLD patients has con fi rmed that only the cytoplasmic content of diac-ylglyceride, and not total or membrane-associated diacylglycerides, predicts hepatic insulin resistance suggesting that hepatic diac-ylglyceride content is a relevant predictor of insulin resistance in…”
Environmental and Genetic Determinants of Fatty Liver in Humans
Kantartzis, K., Schick, F., Häring, H., & Stefan, N. (2010) · Digestive Diseases · doi:10.1159/000282082 · Cited by 32
“Support for this hypothesis comes from studies showing that PNPLA3/adiponutrin has transacetylase functions, and uses diacylglycerol as an acyl acceptor [ , , ,”
ResultMechanism of lipid induced insulin resistance: Activated PKCε is a key regulator
Dasgupta, S., Bhattacharya, S., Maitra, S., Pal, D., Majumdar, S. S., Datta, A., & Bhattacharya, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.01.001 · Cited by 34
Fatty acid represses insulin receptor gene expression by impairing HMGA1 through protein kinase Cε
Dey, D., Bhattacharya, A., Roy, S., & Bhattacharya, S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.183 · Cited by 32
Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes
Chen, S., Sbuh, N., & Veedu, R. N. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0891 · Cited by 30
PKCε plays a causal role in acute ethanol-induced steatosis
Kaiser, J. P., Beier, J. I., Zhang, J., Hoetker, J. D., von Montfort, C., Guo, L., Zheng, Y., Monia, B. P., Bhatnagar, A., & Arteel, G. E. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.11.004 · Cited by 30
Self-citationMcCarty, M. F. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.029 · Cited by 30
Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis
Qin, W., & Weng, J. (2023) · 中国科学通报：英文版 · doi:10.1016/j.scib.2023.06.003 · Cited by 29
Metadata
- Authors
- Samuel, V. T., Liu, Z.-X., Wang, A., Beddow, S. A., Geisler, J. G., Kahn, M., Zhang, X.-M., Monia, B. P., Bhanot, S., & Shulman, G. I.
- Affiliations
- Yale University (US)
- Ionis Pharmaceuticals (United States) (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Shulman, Gerald I.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-03-01
- Volume
- 117
- Issue
- 3
- Pages
- 739-745
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1797607
- OpenAlex
- W2094051977
- Semantic Scholar
- 26809f321fcb7f6db237dd2f0abf76fa612e6a2f
- Cited by
- 497
- References
- 39
- Citations by year
- 2026: 17 · 2025: 10 · 2024: 24 · 2023: 14 · 2022: 19 · 2021: 12 · 2020: 25 · 2019: 26 · 2018: 36 · 2017: 21 · 2016: 37 · 2015: 29 · 2014: 28 · 2013: 25 · 2012: 27
- FWCI
- 24.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (P30 DK45735, R01 DK-40936, DK40936)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK45735, R01-DK40936, R01DK040936, U24DK059635, P30DK045735)
- National Center for Research Resources (K23RR017404, K23 RR-17404)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- protein kinase C epsilon, hepatic insulin resistance, non-alcoholic fatty liver disease, hepatic steatosis, high-fat feeding, insulin receptor, antisense oligonucleotide knockdown, type 2 diabetes, insulin signaling, therapeutic target
- MeSH terms
- Animals, Fatty Liver, Insulin, Insulin Resistance, Male, Receptor, Insulin, Signal Transduction, Oligonucleotides, Antisense, Rats, Sprague-Dawley, Lipid Metabolism, Rats, Protein Kinase C-epsilon
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
